SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: A Phase 2b, Single Arm, Multicenter Trial to Evaluate the Efficacy and Safety of UGN-102 as a Chemoablation Agent in Patients With Low Grade (LG) Non Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk of Recurrence

A Phase 2b, Single-Arm, Multicenter Trial to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk of Recurrence

  • Org Study ID: TC-BC-12
  • Secondary ID:
  • NCT ID: NCT03558503
  • NCT Alias:
  • Sponsor: UroGen Pharma Ltd. - Industry
  • Source: UroGen Pharma Ltd.

Brief Summary

The study is investigating the efficacy and safety of UroGen's UGN-102 to treat patients with Low Grade (LG) Non Muscle Invasive Bladder Cancer (NMIBC) at intermediate risk of recurrence.

Detailed Description

This study is a prospective, open-label, single-arm, multicenter Phase 2b trial designed to
assess the efficacy and safety of UGN-102 treatment instilled in patients diagnosed with LG
NMIBC, including newly diagnosed patients, and determined to have intermediate risk of
progression, defined as 1 or 2 of the following: multiple tumors, solitary tumor >3 cm, or
recurrence (≥ 1 occurrence of LG NMIBC within 1 year of the current diagnosis). Eligible
patients will be treated with 6 weekly instillations of UGN-102.

UGN-102 is a reverse thermal hydrogel formulated with MMC. The product is specifically
formulated to achieve a liquid state at 4°C and to transition to a water-soluble gel at body
temperature. The advantage of delivering Mitomycin to the urinary bladder using UGN-102
relies on preclinical and clinical literature documenting that concentration and dwell time
correlate directly with the therapeutic efficacy of MMC when used to treat Urothelial
Carcinoma (UC)

The ablative effect of UGN-102 will be evaluated at the Primary Disease Evaluation (3 MONTH)
assessment, which will take place 5 weeks ±1 week after the last weekly instillation (3
months after initiation of study medication). Response will be determined based on visual
evaluation by cystoscopy (appearance, number, size, and location of the lesions) and, if
there are remaining lesions, by histopathology of the remaining lesions. CR is defined as
having no detectable disease (NDD) and will be assessed visually during cystoscopy and also
upon urine cytology. In the event that the investigator is not sure, and there is suspect
tissue, a small biopsy will be taken from the suspect tissue to confirm CR in addition to
cystoscopy and urine cytology. Patients who achieve a CR will continue to have monthly
telephone contacts to document any adverse events and changes in concomitant medications and
will be assessed at 6, 9, and 12 months after the first instillation of UGN-102 for evidence
of disease recurrence. The group of patients considered nonresponders (non-CR) will
discontinue the study and continue with standard of care according to their treating

Safety will be determined based on physical examination, laboratory assessments, and a review
of AEs. All safety data will be reviewed on an ongoing basis, including close review and
follow up of any unexpected AE related to UGN-102 and qualified per National Cancer Institute
(NCI) Common Terminology Criteria for Adverse Events (CTCAE) as Grade 3 or 4.

Overal Status Start Date Phase Study Type
Recruiting October 25, 2018 Phase 2 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: Complete response (CR) rate for UGN-102 treatment

Primary Outcome 1 - Time Frame: 3 months after the first instillation of UGN-102


  • Bladder Cancer
  • Urothelial Carcinoma
  • Urothelial Carcinoma Bladder


Inclusion Criteria:

1. ≥ 18 years of age.

2. Willing and able to sign an informed consent and comply with the protocol.

3. Has newly diagnosed or historic LG NMIBC (Ta) histologically confirmed by cold cup
biopsy at screening or within 6 weeks of screening

4. Is at intermediate risk for progression, defined as having 1 or 2 of the following:

1. presence of multiple tumors,

2. solitary tumor >3 cm

3. recurrence (≥ 1 occurrence of LG NMIBC within 1 year of the current diagnosis).

5. Has negative voiding cytology for HG disease at or within 6 weeks of enrollment.

6. Willing to use 2 acceptable forms of effective contraception from enrollment through 6
months post treatment if the female partner is of childbearing potential (defined as
premenopausal women who have not been sterilized).

7. Has adequate organ and bone marrow function as determined by routine laboratory tests
as below:

Leukocytes ≥3,000/μL (≥3×109/L), Absolute neutrophil count ≥1,500/μL (≥1.5×109/L),
Platelets ≥100,000/μL (≥100×109/L), Hemoglobin ≥9.0 mg/dL, Total bilirubin ≤1.5 upper
limit of normal (ULN), AST (SGOT)/ALT (SGPT) ≤2.5 × upper limit of normal (ULN), ALP
≤2.5 × ULN, and Estimated glomerular filtration rate (eGFR) ≥30 mL/min.

8. Has no evidence of active urinary tract infection (UTI) at Screening and Baseline

In the case of symptomatic UTI, the patient will be treated with a full course of
antibiotics, and study medication will be postponed until resolution. In the case of
asymptomatic bacteriuria, the use of prophylactic antibiotics and postponement of study
medication is left to the discretion of the Principal Investigator (PI).

Exclusion Criteria:

1. History of Carcinoma in Situ (CIS) on preliminary cystoscopy within 5 years of

2. Received Bacillus Calmette-Guérin (BCG) treatment for UC within previous 2 years.

3. History of HG papillary UC in the past [2] years

4. Known allergy or sensitivity to mitomycin.

5. Clinically significant urethral stricture that would preclude passage of a urethral

6. History of pelvic radiotherapy.

7. History of:

1. neurogenic bladder

2. active urinary retention

3. any other condition that would prohibit normal voiding

8. Past or current muscle invasive (i.e., T2, T3, T4) or metastatic UC or concurrent
upper tract urothelial carcinoma (UTUC).

9. Has participated in a study with an investigational agent or device within 30 days of

10. History of prior treatment with an intravesical chemotherapeutic agent with the
exception of a single dose of chemotherapy immediately post-TURBT.

11. Has an underlying substance abuse or psychiatric disorder such that, in the opinion of
the investigator, the patient would be unable to comply with the protocol.
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: Robert Robert, MS, CNS, CCRC

Role: Study Director

Affiliation: UroGen pharma Inc

Overall Contact

Name: Robert Kirshoff, MS, CNS, CCRC

Phone: 1-646-768-0772



Facility Status Contact
Mayo Clinic Cancer Center
Phoenix, Arizona 85054
United States
Recruiting Clinical Trials Office - All Mayo Clinic Locations
Arkansas Urology
Little Rock, Arkansas 72211
United States
Recruiting Richard Emanuel D'Anna, MD
Loma Linda University
Loma Linda, California 92350
United States
Recruiting Brian Hu, M.D.
Tower Urology
Los Angeles, California 90048
United States
Recruiting Arnold Cinman, MD
UCLA - University of California, Los Angeles
Los Angeles, California 90095
United States
Recruiting Chamie Karim, MD
Providence Medical Institute
Santa Monica, California 90404
United States
Recruiting Jennifer Linehan, MD
The Urology Center of Colorado
Denver, Colorado 80211
United States
Recruiting Lawrench Karsh, M.D.
Clinical Research Center of Florida
Pompano Beach, Florida 33060
United States
Recruiting Steven Kester, M.D.
University of Iowa
Iowa City, Iowa 52242
United States
John Hopkins University
Baltimore, Maryland 21218
United States
Recruiting Max Kates, MD
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan 48109
United States
Adult & Pediatric Urology, PC
Omaha, Nebraska 68114
United States
Recruiting Trainer Andrew, MD
Urology Las Vegas
Las Vegas, Nevada 89144
United States
Recruiting Michael Verni, M.D.
Manhattan Medical Research
New York, New York 10016
United States
Recruiting Huang William, MD

Weill Cornell Medical College
New York, New York 10065
United States
Recruiting Douglas Scherr, MD
Montefiore Medical Center (Albert Einstein)
New York, New York 10461
United States
Recruiting Alexander Sankin, MD
Western New York Urology Associates
New York, New York 14225
United States
Recruiting Kent Chevli, MD
The University of North Carolina
Chapel Hill, North Carolina 27572
United States
Recruiting Angela Smith, MD
Oregon Urology
Springfield, Oregon 97477
United States
Penn State Hershey State College
Hershey, Pennsylvania 17033
United States
Recruiting Jay Raman, MD
Carolina Urologic Research Center
Myrtle Beach, South Carolina 29572
United States
Recruiting Neil Shore, MD
Urology Associates, P.C
Nashville, Tennessee 37209
United States
Recruiting David Morris, M.D.
Urology San Antonio
Fredericksburg, Texas 78233
United States
Recruiting Daniel Saltzstein, MD
Baylor College of Medicine
Houston, Texas 77030
United States
Carmel Medical Center
Haifa, 3436212
Recruiting Boris Fridman, MD
Rabin Medical Center
Petah tikva, 49372
Recruiting Yaron Erlich, CM
Sheba Medical Center
Ramat Gan, 52621